Key points are not available for this paper at this time.
Autologous BCMA-specific CAR T-cell therapies have substantial activity in multiple myeloma (MM). However, due to logistical limitations and BCMA
Share your take
Add a clinician perspective alongside expert commentary.
Korst et al. (Mon,) studied this question.